Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 07, 2024 18:52 ET | Source: Fibrobiologics, Inc.

FibroBiologics Files 2024 Second Quarter Report

HOUSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending for the development of...
July 15, 2024 09:31 ET | Source: Fibrobiologics, Inc.

FibroBiologics to Present at JonesTrading Healthcare Summit 2024

HOUSTON, July 15, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the...
June 25, 2024 09:31 ET | Source: Fibrobiologics, Inc.

FibroBiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid Technology

HOUSTON, June 25, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the...
June 13, 2024 09:31 ET | Source: Fibrobiologics, Inc.

FibroBiologics Set to Join Russell 2000® Index

HOUSTON, June 13, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the...
June 06, 2024 09:31 ET | Source: Fibrobiologics, Inc.

FibroBiologics to Present at Extracellular Matrix Pharmacology Congress 2024

HOUSTON, June 06, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the...
May 15, 2024 16:30 ET | Source: Fibrobiologics, Inc.

FibroBiologics Announces 2024 Annual Meeting of Stockholders

HOUSTON, May 15, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the...
May 14, 2024 17:24 ET | Source: Fibrobiologics, Inc.

FibroBiologics Files 2024 First Quarter Report

HOUSTON, May 14, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending for the development of...
May 07, 2024 09:31 ET | Source: Fibrobiologics, Inc.

FibroBiologics to Present at the BIO International Convention 2024

HOUSTON, May 07, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the...
April 25, 2024 08:00 ET | Source: Fibrobiologics, Inc.

FibroBiologics Plans to Collaborate with Charles River to Manufacture Fibroblast-based Spheroids

HOUSTON, April 25, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics") and Charles River Laboratories (“Charles River”), a highly respected, global provider of drug...
April 11, 2024 09:31 ET | Source: Fibrobiologics, Inc.

FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office

HOUSTON, April 11, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right